A new Phase 3 clinical trial involving dulaglutide was registered, according to a record dated August 19, 2026. The study, titled "A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes," is registered under identifier NCT07668336.
The trial's current status is listed as not yet recruiting. It is designated as a Phase 3 study, indicating a later-stage clinical trial in the drug development process.
The trial compares orforglipron, an investigational compound identified as LY3502970, against dulaglutide, an approved glucagon-like peptide receptor agonist. The study population is specified as pediatric participants with type 2 diabetes.
No results, enrollment numbers, or timelines beyond the registration date have been disclosed in this record. As the trial has not yet begun recruiting participants, no outcome data or efficacy information is currently available.
Readers interested in learning more about dulaglutide, including its approved uses and mechanism, can consult the compound overview for additional context.